LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 23, 2026, 10:55 AM UTC

ANIP - ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

ANIP

Related stories

Beneficient outlines strategy to eliminate ~$130M HCLP debt, convert $850M preferred into 162,132 shares Beneficient announced a strategy to eliminate the purported ~$130 million HCLP debt and remove Heppner equity and agreements to transform its balance sheet.Key Highlights:Original L impact | REGULATION | Sep 23, 2026, 11:44 AM UTC Ghana's cocoa regulator pitches $1.4 billion domestic financing plan By Emmanuel Bruce and Christian AkorlieGhana Cocoa Board (COCOBOD) is seeking to raise 16.3 billion Ghana cedis ($1.4 billion) from domestic investors to fund cocoa purchases for t L impact | REGULATION | Sep 23, 2026, 11:41 AM UTC CytoSorbents regains Nasdaq $1.00 minimum bid compliance; MVLS shortfall remains under review CytoSorbents regained compliance with Nasdaq's $1.00 minimum bid price requirement after 10 consecutive trading days at or above $1.00.Key Highlights:Original SEC Filing: Cytosorbe L impact | REGULATION | Sep 23, 2026, 11:35 AM UTC AXP pt 370 @ Daxin Sec from 375 L impact | REGULATION | Sep 23, 2026, 11:27 AM UTC ICYMI | SB Energy Plans To Start IPO Marketing After SEC Review Finished L impact | REGULATION | Sep 23, 2026, 11:25 AM UTC AC Immune SA (ACIU) Hits Safety, Immunogenicity Goals in Phase 2 Part 1 AC Immune said Part 1 of its Phase 2 VacSYn trial in early Parkinson’s met safety, tolerability and immunogenicity endpoints, with 100% of treated patients generating antibodies an L impact | REGULATION | Sep 23, 2026, 11:03 AM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.